Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Relapse, non-adherence and community follow-up

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Relapse with immediate loss of safety

Suicidal or violent intent, command hallucinations, severe agitation, catatonia, inability to eat or drink, dangerous driving, missing vulnerable dependants or acute physical illness requires same-day crisis and medical intervention.

Action: Use the agreed crisis route, assess ABCDE and specific harm scenarios, reduce access to means and arrange a direct specialist review in the least restrictive safe setting. Contact necessary supporters or safeguarding services proportionately and clarify who owns the next review.

Role and principles

Recognise individual relapse signatures, understand medication and service non-adherence without blame, restore safe treatment collaboratively, and coordinate physical, psychological, substance, social and safeguarding follow-up across community and crisis services.

Define relapse concretely. A return of voices alone may not represent the person's main deterioration if they remain safe and functional, while loss of sleep, self-care or trust may herald serious change before psychosis is florid. Compare current symptoms, mood, cognition, routines and roles with the person's baseline. Ask what usually changes first and what relatives or clinicians notice. Document the time course and likely triggers, including stress, bereavement, conflict, physical illness, substances, medicine interruption and service transition.

Explore adherence with curiosity. Ask the person to describe a typical day and recent doses rather than demanding a yes or no answer. Adverse effects, limited benefit, disagreement with diagnosis, shame, memory difficulty, chaotic housing, pharmacy access, swallowing, cost of travel, cultural beliefs and previous forced treatment all influence exposure. Check dispensing and administration records with consent where possible. A prescription list is not proof of ingestion, while occasional omission does not explain every deterioration.

Assessment and patient selection

Personal early warning

A repeatable change in sleep, communication, self-care, suspiciousness, activity or substance use appears before the person's previous relapses.

Medication exposure gap

Dispensing, injection or self-report evidence indicates interrupted treatment, but the timing, reason and pharmacological consequences still require clarification.

Functional relapse

Meals, hygiene, bills, attendance, relationships or essential physical treatment deteriorate even when the person reports little change in hallucinations.

Engagement rupture

Avoidance follows fear, adverse effects, disagreement or a coercive experience and may be worsened by repeated threatening or inflexible contact.

Physical mimic

Fluctuating attention, fever, intoxication, medication toxicity or neurological change indicates medical assessment alongside the psychiatric relapse formulation.

Red flags requiring action

  • Rapid loss of sleep with increasing suspiciousness, agitation, commands or disorganisation can precede dangerous relapse and warrants urgent reassessment.
  • A missed clozapine supply or a prolonged gap in a long-acting injectable requires product-specific action and must not be restarted casually.
  • Withdrawal from contact combined with absent food, rent problems, exploitation, fire risk or neglected physical treatment requires active outreach and safeguarding.

Baseline assessment

  1. 01
    Relapse timeline and mental stateFirst step
    Why
    Map change in psychosis, mood, sleep, cognition, behaviour and function against baseline.
    Interpretation and limitations
    The sequence identifies early signs, triggers and current severity; a symptom score alone does not determine crisis need or cause.
  2. 02
    Medication and administration reconciliation
    Why
    Confirm actual oral use, last injection, clozapine gap, interactions, smoking and adverse effects.
    Interpretation and limitations
    Exact timing determines safe restart and whether inadequate exposure is plausible; never infer ingestion from an active prescription.
  3. 03
    Physical and substance assessment
    Why
    Detect delirium, infection, intoxication, withdrawal, toxicity, injury and treatment complications.
    Interpretation and limitations
    Abnormal attention, observations or neurology redirect urgent care; substance involvement can coexist with a primary relapse and needs integrated treatment.
  4. 04
    Scenario-based risk formulation
    Why
    Assess suicide, violence, driving, self-neglect, vulnerability, dependants, means and safeguards.
    Interpretation and limitations
    Link each plausible harm pathway to an intervention and review trigger rather than using a categorical label as the management decision.
  5. 05

Interventions

01Early deteriorationAct on the personal signatureFirst stepRecognised changes in sleep, suspiciousness, self-care, contact or substance use emerge.+
  1. 1Contact the person through agreed channels, assess physiological state and specific harm scenarios and compare change with prior relapse patterns.
  2. 2Review medicines, exposure, adverse effects, substances, stress and practical needs and involve consented supporters when helpful.
  3. 3Increase follow-up, psychological and practical support and obtain specialist medication review before the presentation becomes an avoidable crisis.
02Treatment interruptionReconcile before restartingOral doses, clozapine or a long-acting injection have been missed for an uncertain period.+
  1. 1Verify the exact product, dose, last confirmed administration, reason for interruption, current symptoms and any withdrawal or toxicity signs.

Targets, monitoring and follow-up

  • Track the person's own relapse indicators, sleep, psychosis, mood, function, substances and safety at a frequency matched to current instability.
  • Reconcile medication exposure and adverse effects at every transition, including exact clozapine gaps and long-acting injection dates.
  • Maintain antipsychotic metabolic, cardiovascular, movement and prolactin monitoring and ensure abnormal results generate an owned action.
  • Review housing, food, finances, relationships, education, employment, exploitation and caring responsibilities because social change can precede clinical crisis.
  • Test crisis contacts and transition arrangements in practice and revise the plan after missed appointments, emergency attendance or a successful early intervention.

Special situations

Adherence has a reason

Understanding benefit, burden, routine and trust produces safer solutions than labelling a person unmotivated or unreliable.

Function can lead symptoms

Bills, meals or sleep may deteriorate before hallucinations become obvious, making ordinary routines valuable early warning data.

Plans need product detail

A useful crisis document distinguishes routine oral omission from clozapine interruption and each long-acting injection's missed-dose pathway.

Contact can feel threatening

Outreach after persecutory experiences or coercion should use agreed people, channels and language while still responding to serious danger.

Relapse reviews include services

Unclear responsibility, delayed access or unacted results are modifiable contributors and should not be rewritten as patient failure.

Common pitfalls

  1. 01

    Using non-compliant as the explanation without asking about benefit, adverse effects and practical barriers.

  2. 02

    Restarting clozapine or a depot from the old prescription without verifying the treatment gap.

  3. 03

    Equating medication collection with recovery while self-care, housing or occupation deteriorates.

  4. 04

    Using a generic relapse checklist instead of learning the person's own sequence and preferred response.

  5. 05

    Missing delirium, intoxication or toxicity because previous psychiatric relapse appears similar.

  6. 06

    Discharging from crisis care without a named receiving clinician and confirmed first contact.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Clozapine interruption safety

A community patient taking clozapine reports that no tablets have been taken for four days and asks to restart the former full dose tonight. What is the safest response?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG178 psychosis and schizophrenia recommendationsRelapse, antipsychotic review, adherence, psychological care and long-term community follow-up.
  • NICE NG181 rehabilitation recommendationsCollaborative care planning, rehabilitation, physical health, transitions and missed-contact principles.
  • NICE CG120 psychosis with substance misuseIntegrated assessment and treatment when substance exposure contributes to relapse.
  • Clozaril tablets summary of product characteristicsInterruption, re-titration, registered monitoring and acute clozapine safety requirements.
  • GMC decision making and consentSupported decisions, capacity and collaborative treatment change.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Medication reconciliation is safety critical. Establish the exact last clozapine dose because an interruption may require specialist re-titration. Verify the last long-acting injection and consult its missed-dose algorithm before administration. Review withdrawal effects, anticholinergic rebound, sleep change and interactions. Tobacco smoking, infection and other medicines can change clozapine exposure. When treatment is resumed, choose the lowest-risk route and monitoring plan for the identified gap rather than automatically restoring the previous regimen.

Community care integrates relapse treatment with daily life. Reassess suicide, violence, self-neglect, exploitation, dependants, driving and physical illness. Offer psychological coping work, family intervention, integrated substance care and practical support for housing, finances, food, education and employment. Use an advance statement or collaborative crisis plan to record preferred settings, contacts and treatments, while explaining that future emergencies still require contemporaneous capacity and legal assessment. Maintain primary-care physical monitoring and communicate abnormal results.

After a crisis, review the system as well as the patient. Identify missed warning signs, delayed referrals, inaccessible appointments, ambiguous prescribing ownership or information not shared. Ask how restraint, admission or police contact affected trust and what could reduce future trauma. Update the relapse plan with tested actions and arrange a named follow-up before discharge from crisis care. If the person misses it, responsibility remains with the service until risk and alternative arrangements are actively reviewed.

Key points

  • Relapse is a clinically important worsening of symptoms, distress, behaviour or function and should be defined against the person's own recovery baseline.
  • Common early changes include sleep disruption, withdrawal, reduced self-care, suspiciousness, irritability, unusual online activity, substance use and missed appointments, but signatures are individual.
  • Non-adherence is a description of treatment exposure, not a character judgement; explore adverse effects, beliefs, memory, cost, access, stigma, coercion and practical routines.
  • Confirm what was actually taken and stopped, including last oral dose, injection date, clozapine gap, smoking, substances and other medicines, before resuming or switching.
  • Use shared decision making to address the cause: adverse-effect treatment, simplified dosing, reminders, outreach, formulation change or a different therapeutic option may be appropriate.
  • Create a written relapse plan listing personal warning signs, actions, preferred contacts, information-sharing choices, physical red flags and product-specific medication instructions.
  • Community follow-up should measure function, physical health, treatment burden, substances, housing, relationships and occupation rather than medication collection alone.
  • After crisis, review what helped, repair any harmful care experience and perform a warm handover so responsibility does not disappear between services.
  • New fever, confusion, focal neurology, intoxication or medication toxicity may mimic psychiatric relapse and demands a physical assessment.
  • Conflict with family or services after coercive care can intensify risk and requires trauma-informed engagement rather than escalating confrontation.
    • Barrier and support-network review
    Why
    Identify access, memory, communication, relationship, housing, finance and trust factors affecting follow-up.
    Interpretation and limitations
    A modifiable service or practical barrier should change the care offer; repeated non-attendance alone does not prove a lack of need.
    2
    Use the SmPC and specialist or pharmacy pathway for re-titration, oral cover or missed injection rather than resuming from memory.
  • 3Address the underlying barrier collaboratively and arrange early monitoring of response, adverse effects, physical health and renewed exposure.
    • 03Post-crisis reviewRepair, learn and hand overAcute relapse has stabilised enough for return to community follow-up.+
    1. 1Review the episode with the person and supporters, identifying triggers, early signs, effective actions and distressing or coercive aspects of care.
    2. 2Update the written crisis, medication, safeguarding and physical-health plan and confirm accessible contacts and information-sharing preferences.
    3. 3Complete a warm handover with a named clinician, prescription supply, due monitoring and first appointment, retaining outreach responsibility if contact fails.